Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Checkpoint inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC). However, only a minority of patients demonstrate a durable clinical response. PD-L1 scoring is currently the only biomarker measure routinely used to select patients for immunotherapy, but its predictiv...

Full description

Bibliographic Details
Main Authors: Mohamed Eltahir, Johan Isaksson, Johanna Sofia Margareta Mattsson, Klas Kärre, Johan Botling, Martin Lord, Sara M. Mangsbo, Patrick Micke
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
lung cancer
biomarkers
liquid biopsy
immune checkpoint inhibitors
PD-L1
Online Access:https://www.mdpi.com/2072-6694/13/13/3116

Internet

https://www.mdpi.com/2072-6694/13/13/3116

Similar Items